medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Number 2

<< Back Next >>

Ann Hepatol 2011; 10 (2)

The liver is the key organ for the development of metabolic syndrome

Franco-Bourland RE, Méndez-Sánchez N

Language: English
References: 15
Page: 216-217
PDF size: 26.85 Kb.


Text Extraction

The metabolic syndrome affects more than a third of the US and Mexican populations, predisposing to the development of some metabolic disorders.
In fact, it is well recognized that subjects with generalized obesity suffer from a high risk of insulin resistance and its metabolic complications, such as type 2 diabetes mellitus, hypertriglyceridemia, low levels of high density lipoprotein cholesterol, hypertension, hepatic steatosis, hyperuricemia, and atherosclerotic vascular disease.


REFERENCES

  1. Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. Diabetes. 2010;2:180-93.

  2. Rojas R, Aguilar-Salinas CA, Jiménez-Corona A, Shamah- Levy T, Rauda J, Avila-Burgos L, Villalpando S, Ponce EL. Metabolic syndrome in Mexican adults: results from the National Health and Nutrition Survey 2006. Salud Publica Mex. 2010; 52 (Suppl 1):S11-8.

  3. Garg A, Misra A. Hepatic steatosis, insulin resistance, and adipose tissue disorders. J Clin Endocrinol Metab. 2002; 87: 3019–22.

  4. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988; 37: 1595-607.

  5. Méndez-Sánchez N, Chávez-Tapia NC, Zamora-Valdés D, Medina-Santillán R, Uribe M. Hepatobiliary diseases and insulin resistance. Curr Med Chem. 2007; 14: 1988-99.

  6. Kim SP, Ellmerer M, Van Citters GW, Bergman RN. Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate fat diet in the dog. Diabetes. 2003; 52: 2453-60.

  7. Czaja MJ. JNK regulation of hepatic manifestations of the metabolic syndrome. Trends Endocrinol Metab. 2010; 21: 707-13.

  8. Wasada T, Kasahara T, Wada J, Jimba S, Fujimaki R, Nakagami T, Iwamoto Y. Hepatic steatosis rather than visceral adiposity is more closely associated with insulin resistance in the early stage of obesity. Metabolism Clin Exp 2008; 57: 980-985.

  9. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, Goto T, Westerbacka J, Sovijärvi A, Halawaara J, Yki-Järvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023-8.

  10. Kotronen A, Seppälä-Lindroos A, Bergholm R, Yki-Järvinen H Tissue specificity of insulin resistance in humans: fat in the liver rather than muscle is associated with features of the metabolic syndrome. Diabetologia 2008: 51: 130-8.

  11. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI . Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004; 279: 32345-53.

  12. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR, Mullins JJ. Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 2004; 101: 7088-93.

  13. Rizza RA, Mandarino LJ, Genest J, Baker BA, Gerich JE. Production of insulin resistance by hyperinsulinaemia in man. Diabetologia 1985; 28: 70–75.

  14. Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, Okunade A, Klein S. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009; 106: 15430–5.

  15. Fabbrini E, Tamboli RA, Magkos F, Marks-Shulman PA, Eckhauser AW, Richards WO, Klein S, Abumrad NN. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology 2010; 139: 448-55.




2020     |     www.medigraphic.com